This medicine is authorised for use in the European Union.


Verquvo is a medicine used to treat adults with long-term heart failure with reduced ejection fraction who recently received intravenous (into the vein) treatment because of worsening of their symptoms. Heart failure with reduced ejection fraction is when the heart does not pump blood as well as it should, especially when the amount of blood being pumped out of the heart is less than the body needs. Some common symptoms of heart failure are shortness of breath, tiredness, or swelling caused by a build-up of fluid.

Verquvo contains the active substance vericiguat.

This EPAR was last updated on 27/07/2021

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Heart Failure
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Bayer AG
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Kaiser-Wilhelm-Allee 1
51373 Leverkusen

Product information

16/07/2021 Verquvo - EMEA/H/C/005319 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Cardiac therapy

Therapeutic indication

Treatment of symptomatic chronic heart failure

Assessment history

How useful was this page?

Add your rating
2 ratings